Background. We aimed to quantify the rate of Mycobacterium tuberculosis disease (TB) among a cohort of patients with rheumatoid arthritis (RA) and to assess whether the independent use of disease-modifying antirheumatic drugs (DMARDs) is associated with the risk of developing TB.
It is generally believed that rheumatologic diseases, such as systemic lupus erythematosus and possibly rheumatoid arthritis (RA), may be associated with an increased risk of Mycobacterium tuberculosis disease (TB) [1, 2] . Although the rheumatologic diseases themselves have been associated with this risk increase, it is suspected that immunosuppressant therapies used to treat RA may also increase the risk of TB. Indeed, patients with RA receiving a mean prednisone dosage of 15-20 mg/day/year have been shown to have an increased risk of developing active TB [3] .
The treatment options available for RA and for certain other autoimmune diseases were recently substantially broadened with the arrival of the TNF-a inhibitors (including etanercept and infliximab) in 1998. According to reported case-series and surveillance systems, the use of these biological disease-modifying an-tirheumatic drugs (DMARDs) may be associated with an increase in the risk of developing active TB, compared with that of the general population [2, [4] [5] [6] . The magnitude of the increase in TB risk that is associated with either of these agents, as well as with the human IL-1 receptor antagonist anakinra (another biological DMARD), is unknown. In addition, it is unclear whether this effect is modified by other antirheumatic drugs. We aimed to quantify the rate of TB among a cohort of patients with RA and to assess whether the use of biological DMARDs and other treatments for RA are associated with the risk of developing TB.
METHODS
Study design and data source. The study was performed using the America-based PharMetrics PatientCentric Database (PharMetrics). This database consists of standardized, patient-level information on medical and pharmaceutical claims data from 185 different managed care organizations and currently contains information on 160 million subjects. Patient privacy is protected through encryption algorithms that are performed by each contributing organization.
A cohort of all subjects with у1 occurrence of a diagnosis of RA (International Classification of Disease, Ninth Revision [ICD-9], code 714) during an inpatient or outpatient visit was formed. Cohort subjects were further restricted to those who were dispensed у1 prescription for any anti-RA drug, including DMARDs, during the period of September 1998 through December 2003. The subjects entered the cohort on the date that the first prescription for an anti-RA drug was dispensed after a year of eligibility in a health insurance plan. They were observed until the earliest of the date of termination of enrollment in the health plan, the date of death, the end of the study period (31 December 2003), or the date of the outcome of interest (namely TB). Cases of TB and their clinical presentations were identified in the cohort by ICD-9 code 010-018. Subjects who had TB prior to cohort entry were excluded. Subjects were aged у18 years at cohort entry. Nested case-control study design. We used a nested casecontrol study design within the RA cohort, an efficient approach to address the complex patterns of drug exposure over time with insignificant loss of power [7] . For each case of TB, we randomly selected 100 control subjects from the cohort after matching for the date of cohort entry and ensuring that control subjects were at risk on the day that the case occurred. This date was designated as the index date.
Exposure measurement. All drugs received during the observation period were identified from dispensed prescription data. The type, date of filling, and quantity of each prescription were obtained from the database. For purpose of comparisons, we considered exposure to anti-RA drugs in the year prior to the index date. The DMARD exposure categories were exposure to biological DMARDS (infliximab, etanercept, and anakinra), exposure to traditional DMARDS (methotrexate, leflunomide, hydrohychloroquine, sulfasalazine, auranofin, cyclosporine, penicillamine, and cyclophosphamide), and no DMARD use at the index date. Patients could thus contribute to 11 exposure category. Adalimumab, another TNF inhibitor, was introduced in 2002, and was therefore not part of our study.
Covariate information. Age and sex were used as covariates to define the study sample. The assessments of the comorbid clinical conditions known to increase the risk of TBdiabetes (ICD-9, 250.0-250.9); chronic renal failure (ICD-9, 585); hemodialysis (ICD-9, V56.0); solid organ transplantation such as renal transplantation (ICD-9, V42.0) or heart transplantation (ICD-9, V42.1); carcinoma of head (ICD-9, 173.4) or neck (ICD-9, 195.0); and silicosis (ICD-9, 502) [8] -were based on diagnoses made during the period prior to the index date. Other drugs commonly used as concomitant treatment for rheumatoid arthritis-namely, the non-DMARDS such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and cyclyoxygenase-2 (COX-2) inhibitors-were used as covariates to adjust for disease severity. For corticosteroids and COX-2 inhibitors, current exposure was defined by prescriptions dispensed in the 30-day period prior to the index date.
Analysis. Total person-years of follow-up were used to estimate the overall rate of occurrence of TB for the entire cohort. Conditional logistic regression was used in the nested casecontrol analysis to estimate the rate ratio (RR) of TB for any use of biological or traditional DMARDs during the year before the index date. Dose response of DMARD use in terms of the quantity of prescriptions and subsequent risk of TB was also estimated. All analyses were adjusted for the concurrent use of other DMARDs or non-DMARDs, as well as for age, sex, and all comorbid clinical conditions. As corticosteroids are a known risk factor for the development of TB, we assessed the interaction between DMARDs and the current use of corticosteroids. Analyses were performed using SAS (SAS Institute).
RESULTS
The cohort consisted of 112,300 patients with RA, of whom 73% were female. The median subject age at the time of cohort entry was 54 years, with 54% of the cohort aged 41-60 years. There were 386 cases of TB identified during the follow-up period, for an overall rate of 2.19 (95% CI, 1.97-2.41) cases per 1000 person-years of follow-up. For those exposed to TNF blocking agents the rate was 2.57 (95% CI, 1.89-3.26) cases per 1000 person-years.
Among cases of TB, the proportion of pulmonary-only form of TB (versus extrapulmonary or miliary TB) was greater for those exposed to biological DMARDs (73.2%) than for those exposed to traditional antirheumatic drugs (34.5%) or who used no DMARDs at all (45.7%). The median time from the first prescription until presentation of TB for those patients who received infliximab was 17 weeks (range, 1-71 weeks); for those who received etanercept, 79 weeks (range, 3-168 weeks); and for those who received anakinra, 62 weeks (range, 7-138 weeks). Table 1 compares the baseline characteristics of the study subjects with TB and the control subjects. Patients with TB were significantly younger than were control subjects. Case subjects showed a significantly higher rate of diabetes and other comorbid conditions and were more likely to be exposed to biological and traditional DMARDs and glucocorticosteroids during the 1-year baseline period. Table 2 shows the characteristics of control subjects according to the different exposure categories. The major difference lies in corticosteroid use among nonusers and users of DMARDs (22% and 42%, respectively). Table 3 shows that the adjusted RR of TB for biological DMARD use was 1.5 (95% CI, 1.1-1.9). The RR varied from 1.2 to 1.6 for the 3 biological DMARDs of interest, with only infliximab revealing a significantly increased risk for TB (RR, 1.6; 95% CI, 1.0-2.6). Traditional DMARDs were also inde- pendently associated with TB (RR, 1.2; 95% CI, 1.0-1.5).
Among patients with TB exposed to biological DMARDs, the median number of doses prescribed in the previous year to index date was 5 (range, 1-33). Among patients with TB exposed to traditional DMARDs in the same fashion, the median number of doses was 6 (range, 1-55). The risk of TB associated with drug use decreased as the number of DMARD doses prescribed increased (table 4) . The differential impact of anti-RA medications by concurrent use of corticosteroids was tested by the inclusion of interaction terms. The interaction between biological and traditional DMARD use and current corticosteroid use was significant ( and , respectively). We thus stratified our P p .018 P p .006 analysis of DMARD use per corticosteroid use compared with controls. Overall, RRs for DMARD use and the risk of TB were lower among current users of corticosteroids than among noncurrent users (table 5) . Among noncurrent users of corticosteroids, biological and traditional DMARD use reveals a significant association with an increased risk of TB; among current users of corticosteroids, the RRs for biological and traditional DMARD use and TB with were lower than 1.
DISCUSSION
To our knowledge, this is the first study that attempts to clarify the independent contributions of different classes of medication to the risk of TB among patients with RA. We found that the use of biological and traditional DMARDs is associated with an increased risk of developing TB in patients with RA, mainly among noncurrent users of corticosteroids. The risk increase seen with biological DMARDs appears to be consistent for the 3 agents under study-namely, the TNF-blocking agents infliximab and etanercept and the IL-1-blocking agent anakinra.
The major strengths of our study were the size of our observational cohort (derived from a large drug claims registry) and the number of TB cases, as well as the potential time of follow-up of 15 years. We identified 112,300 patients with RA aged у18 years among whom 386 cases of TB occurred after exposure to antirheumatic drugs. The extent to which patients who have RA will demonstrate an excess risk of TB will depend on the prevalence of the disease, latent TB infection, and potential risk factors in the community. Unfortunately, we could not capture other factors associated with the risk of TB disease that could influence the baseline risk of TB disease while being exposed to RA drugs; these include country of birth, socioeconomic status, a history of recent contact with an individual with TB, and the presence of TB-associated abnormalities on a chest radiograph [8] . We also did not collect any information on HIV infection status or smoking behavior [9, 10] .
Our observed incidence of TB of 2.57 (95% CI, 1.89-3.26) per 1000 person-years among patients with RA treated with a TNF-blocking agent is within the range of a recent study reporting an incidence of 1.18 (95% CI, 0.58-2.1) per 1000 person-years among a large cohort of patients with RA in Sweden [11] but higher than what was previously reported for patients with RA exposed to specific biological DMARDs [4, 5, 12, 13] . That most of the estimates from the latter study came from pharmacovigilance data or relied on passive reports, and that they could have underestimated the true TB rate through underreporting, suggests a significant issue with adverse events reports [14] . It is difficult to accurately calculate incidence using pharmacovigilance data, because the true number of exposed patients is essentially unknown. TB incidence based on a relatively short time span could also underestimate the true incidence, especially for those drugs with a longer time to presentation of TB (such as certain biological DMARDs). Another potential explanation for our observed incidence of TB that is higher than previously reported would be that our cohort of adults with RA overrepresented individuals at risk for TB. Unfortunately, we could not adjust for this potential confounder in our study.
We found that the proportion of subjects with the pulmonary form of TB was greater among those exposed to biological DMARDs (72%). This somewhat contradicts previously reported clinical presentations in relatively small numbers of TB cases among patients with RA who are treated with specific biological DMARDs [2, 4, 5, 12] . However, a recent study that involved a cohort of 62,321 patients with RA reported a similar proportion of patients with pulmonary TB (67%) among 15 TB cases exposed to biological DMARDs [11] .
As suggested by others [12, 15, 16] , time until presentation of TB for the different biological DMARDs may represent distinct pharmacokinetics and/or pharmacodynamics of each drug's immunosuppressive activity. Our results are consistent with previous results [5, 13, 17] , although we are the first to report a time of onset of TB among anakinra users.
DMARDs are often used in conjunction with other immunosuppressive therapies, particularly corticosteroids. On the basis of the individual increase in risk of TB among patients with RA treated with these agents and the significant interaction term in the modeling process, we stratified the analysis of the use of DMARDs and the subsequent risk of TB according to levels of exposure to corticosteroids. We found that the risk of NOTE. Drug exposure monitored in the year before index date. Comparison group are control subjects, as in table 3. Data are adjusted for age, sex, all comorbid clinical conditions, and one another. DMARD, disease-modifying antirheumatic drug; NE, not estimable (i.e., no anakinra-exposed individual simultaneously exposed to current corticosteroids). TB differs according to the level of exposure to steroids. Indeed, when DMARDs were used in therapy for RA in the absence of corticosteroids, we observed an increase in the risk of TB in both biological DMARD users and traditional DMARD users. Conversely, neither biological nor traditional DMARD use is associated with TB when corticosteroids are part of the current treatment (table 5) . We also ran the same group of analyses looking at any corticosteroid use, as well as at the use of 13 prescriptions for steroids in the previous year (instead of looking at just current use). Minimal changes in the RR were observed. In patients receiving combined therapy, the doses of each individual agent may be below the TB threshold, and a synergic effect may not be observed because each agent works through different mechanisms. Unfortunately, our source of data did not provide dosages.
One explanation for the relatively small increase in risk for TB with exposure to DMARDs that was observed in our study group could be related to the depletion of TB-susceptible patients with RA [18] . We recorded subjects' drug use in the year before the index date; patients who could tolerate DMARDs probably tended to continue to receive it, whereas those who could not selected themselves out of the at-risk population (especially first-time users) by developing TB. This is exemplified by the inverse relationship observed in this study of the increasing number of administered doses of DMARDs and the decreased risk of TB. Another possible explanation for the small observed increase in risk is that different medications are preferentially prescribed to different patients with various degrees of illness and baseline risks for TB disease [15] . This channeling bias has been documented in patients with RA receiving COX-2 inhibitors [19] . In our study, a patient originating from an area with high endemicity or who has chest radiograph abnormalities-and, therefore, has an increased risk of TB reactivation-may have been prescribed anakinra, because this drug has not been associated in the past with TB (as have the other biological DMARDs). On the other hand, if biological DMARDs in general are not readily prescribed to at-risk groups, then the observed RR underestimates the true risk.
Our study has several limitations. The study was based entirely on computerized claims data (with limited available clinical data), which makes it impossible to validate the diagnosis of TB. We structured the data so that DMARD exposure preceded the diagnosis of TB; however, the administrative nature of the database cannot completely exclude a misclassification of occurrence of TB disease. It was also not possible to confirm the diagnosis of RA, although the presence of such a diagnosis combined with a dispensed prescription for an anti-RA drug likely increases the validity of the diagnosis. Residual confounding by disease severity may also still be present, although a recent study showed that confounding by factors not measured in Medicare claims data tended to slightly underestimate the association between rare adverse events from medication use, but was unlikely to cause important bias [20] . Finally, although these are highly specific drugs, the completeness of data on prescription drug use is unknown. The PharMetrics databank obtains data on paid retail and mail order prescription claims. Any information on medications not covered by prescription coverage (i.e., medication for which patients paid cash) or on over-the-counter drugs would not be included in the data; however, this is not likely to occur in the case of RA.
Despite these limitations, this is the first report to demonstrate the independent effect of biological or traditional DMARD use in modulating the risk of developing TB in patients with RA, especially among noncurrent users of corticosteroids. The results of this study are consistent with published recommendations that warrant screening for active TB and latent TB before initiation of immunosuppressive therapy [8, [21] [22] [23] [24] . A recent summary of trials that addressed the safety of anakinra reported no cases of TB among patients with RA who had a wide variety of comorbid conditions and who were taking a variety of medications [25] . In contrast, our results do not support the use of anakinra in patients who are nonusers of corticosteroids and who cannot be treated with a TNFblocking agent because of a history of active TB or latent TB and who cannot tolerate appropriate therapy for the latter [26] . Additional explorations regarding the optimal therapeutic approach to treatment of TB for patients who have RA and who receive DMARD therapy are needed [27] .
